Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Stephen, Shumack"'
Autor:
Lynda Spelman, Andrew E. Potter, Chris Baker, Stephen Shumack, Robert Sinclair, David Christie, Bradley Wong, Peter Foley, Steven Hacker, Cody C. Allison, the National Dermatology Radiation Oncology Registry (NDROR) investigators and sites
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 2, Pp 487-497 (2024)
Abstract Background Widefield radiation therapy (RT) has emerged as a treatment option for extensive skin field cancerization (ESFC), with or without keratinocyte cancer (KC). Objectives To assess the long‐term efficacy, safety, cosmesis and qualit
Externí odkaz:
https://doaj.org/article/1fcca7d2552f4cb7ae75c3cd0c583613
Autor:
Andrew E. Potter, Christopher Baker, Stephen Shumack, Robert Sinclair, Walter J. Curran, David Christie, Bradley Wong, Peter Foley, Peter O’Brien, Lynda Spelman, on behalf of the National Dermatology Radiation Oncology Registry (NDROR) investigators and sites.
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 5, Pp 2634-2642 (2022)
Purpose Evaluate the use of widefield radiation therapy (RT) in the management of extensive skin field cancerization (ESFC) with/without keratinocyte cancer (KC). Methods The National Dermatology Radiation Oncology Registry is a multidisciplinary col
Externí odkaz:
https://doaj.org/article/c0dbad99f7ef41d1aba55d022cfc63d4
Autor:
Marjolein de Bruin-Weller, Mette Deleuran, Tilo Biedermann, Robert Bissonnette, Peter Foley, Giampiero Girolomoni, Jana Hercogová, Chih-Ho Hong, Norito Katoh, Andrew Pink, Marie-Aleth Richard, Stephen Shumack, Juan Francisco Silvestre, Jacob P. Thyssen, Stephan Weidinger
Publikováno v:
Acta Dermato-Venereologica, Vol 103 (2023)
Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermat
Externí odkaz:
https://doaj.org/article/4f64746c251d43be8b51d8e068e15cc2
Autor:
Yandong Shen, Luke Coyle, Ian Kerridge, William Stevenson, Christopher Arthur, Naomi McKinlay, Keith Fay, Christopher Ward, Matthew Greenwood, Oliver Giles Best, Ann Solterbeck, Alexander Guminski, Stephen Shumack, Stephen P. Mulligan
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 129-138 (2022)
Abstract Chronic lymphocytic leukaemia (CLL) is invariably accompanied by some degree of immune failure, and CLL patients have a high rate of second primary malignancy (SPM) compared to the general population. We comprehensively documented the incide
Externí odkaz:
https://doaj.org/article/bfe51b01464c452490529972a47017e0
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 1, Pp 173-177 (2022)
Introduction Vitiligo is an autoimmune disorder characterized by progressive loss of melanocytes, leading to cutaneous depigmentation. Vitiligo has significant psychosocial impacts on patients and is challenging to manage with limited treatment optio
Externí odkaz:
https://doaj.org/article/cb818555119e41e6a108571251d21ddd
Publikováno v:
Pigment International, Vol 9, Iss 2, Pp 127-130 (2022)
Background: Vitiligo is an autoimmune skin disorder characterized by patches of depigmentation due to loss of melanocytes. Vitiligo is associated with significant psychosocial burden, with prior studies showing links with psychiatric comorbidities su
Externí odkaz:
https://doaj.org/article/dd18c998539b4d3db253683f25e325d4
Publikováno v:
Australasian Journal of Dermatology. 64:291-295
Autor:
Stephen K. Tyring, Phoebe Rich, Yayoi Tada, Stefan Beeck, Izabella Messina, Jie Liu, Xiaohong Huang, Stephen Shumack
Publikováno v:
Dermatology and Therapy. 13:595-608
Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD.This phase 2, multicenter, randomized, double-bli
Autor:
Marjolein De Bruin-Weller, Tilo Biedermann, Robert Bissonnette, Mette Deleuran, Peter Foley, Giampiero Girolomoni, Jana Hercogová, Chih-Ho Hong, Norito Katoh, Andrew E. Pink, Marie-Aleth Richard, Stephen Shumack, Juan F. Silvestre, Stephan Weidinger
Publikováno v:
Acta Dermato-Venereologica, Vol 101, Iss 2, p adv00402 (2021)
Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought to reach international consensus through an eDelphi process on a core set of recommendations for such an approach
Externí odkaz:
https://doaj.org/article/c946a16099f342538febe70c6a2106da
Autor:
Vivian Y, Shi, Tina, Bhutani, Luz, Fonacier, Mette, Deleuran, Stephen, Shumack, Hernan, Valdez, Fan, Zhang, Gary L, Chan, Michael C, Cameron, Natalie C, Yin
Publikováno v:
Shi, V Y, Bhutani, T, Fonacier, L, Deleuran, M, Shumack, S, Valdez, H, Zhang, F, Chan, G L, Cameron, M C & Yin, N C 2022, ' Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND) ', Journal of the American Academy of Dermatology, vol. 87, no. 2, pp. 351-358 . https://doi.org/10.1016/j.jaad.2022.04.009
BACKGROUND: Abrocitinib efficacy by prior dupilumab response status in patients with moderate-to-severe atopic dermatitis (AD) has not previously been assessed in phase 3 studies.OBJECTIVE: Examine efficacy and safety of abrocitinib among patients wh